


Serial No. 10/030,189  
Response to Office Action of July 1, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1 (currently amended): A serine protease inhibitor compound of formula (I)



wherein:

R<sub>2</sub> is a 5 or 6 membered aromatic carbon ring optionally interrupted by a nitrogen, oxygen or sulphur ring atom, optionally being substituted in the 3 and/or 4 position (in relation to the point of attachment of X-X) by halo, nitro, thiol, haloalkoxy, hydrazido, alkylhydrazido, amino, cyano, haloalkyl, alkylthio, alkenyl, alkynyl, acylamino, tri or difluoromethoxy, carboxy, acyloxy, MeSO<sub>2</sub>- or R<sub>1</sub>, or the substituents at the 3 and 4 positions taken together form a fused ring which is a 5 or 6 membered carbocyclic or heterocyclic ring optionally substituted by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R<sub>1j</sub>, and optionally substituted in the position alpha to the X-X group (i.e. 6 position for a six membered aromatic ring etc) by amino, hydroxy, halo, alkyl, carboxy, alkoxy, carbonyl, cyano, amido, aminoalkyl, alkoxy or alkylthio with the proviso that R<sub>2</sub> cannot be aminoisoquinolyl;

Serial No. 10/030,189  
Response to Office Action of July 1, 2003

each X independently is a C, N, O or S atom or a CO, CR<sub>1a</sub>, C(R<sub>1a</sub>)<sub>2</sub> or NR<sub>1a</sub> group, at least one X being C, CO, CR<sub>1a</sub> or C(R<sub>1a</sub>)<sub>2</sub>;

each R<sub>1a</sub> independently represents hydrogen, hydroxyl, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy carbonyl, alkylaminocarbonyl, alkoxy carbonylamino, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl;

R<sub>1</sub> is as defined for R<sub>1a</sub>, provided that R<sub>1</sub> is not unsubstituted aminoalkyl;

Y (the  $\alpha$ -atom) is a nitrogen atom or a CR<sub>1b</sub> group;

Cy is a saturated or unsaturated, mono or poly cyclic, homo or heterocyclic group, optionally substituted by groups R<sub>3a</sub> or R<sub>3i</sub>X<sub>i</sub>;

each R<sub>3a</sub> independently is R<sub>1c</sub>, amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkylimidazolyl, thiazolyl, alkylthiazolyl, alkyloxazolyl, oxazolyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy, haloalkyl, a group of the formula -C(X<sup>3</sup>)N(R<sup>11</sup>)R<sup>12</sup> (wherein X<sup>3</sup> is O or S; and R<sup>11</sup> and R<sup>12</sup> are independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group), or -OCH<sub>2</sub>O- which is bonded to two adjacent ring atoms in Cy;

X<sub>i</sub> is a bond, O, NH or CH<sub>2</sub>;

R<sub>3i</sub> is phenyl, pyridyl or pyrimidinyl optionally substituted by R<sub>3a</sub>; and


R<sub>1b</sub>, R<sub>1c</sub> and R<sub>1j</sub> are as defined for R<sub>1a</sub>,

L is CO;

and -Lp(D)<sub>n</sub> - ~~L-Lp(D)<sub>n</sub>~~ is of the formula:

Serial No. 10/030,189

Response to Office Action of July 1, 2003



wherein:

q is ~~1~~ or 2;

Q is -O- or -NH-;

and R<sub>q</sub> is R<sub>C</sub> which is pyridyl, pyrimidin-4-yl, pyridazin-3-yl, pyridazin-4-yl or phenyl (which phenyl or pyridyl group may bear a fluoro, chloro, alkyl, CONH<sub>2</sub>, SO<sub>2</sub>NH<sub>2</sub>, dialkylaminosulphonyl, methoxy, methylthio, alkylsulphonyl, alkylaminosulphonyl, alkylaminocarbonyl, amino, alkoxy, carbonyl, acetyl, cyano, ethoxy, nitro, hydroxy, alkylsulphonylamino, triazolyl or tetrazolyl substituent); or a physiologically-tolerable salt thereof.

2 (currently amended): A serine protease inhibitor compound according to Claim 1

wherein:

R<sub>2</sub> is a 5 or 6 membered aromatic carbon ring optionally interrupted by a nitrogen, oxygen or sulphur ring atom, optionally being substituted in the 3 and/or 4 position (in relation to the point of attachment of X-X) by halo, nitro, thiol, haloalkoxy, hydrazido, alkylhydrazido, amino, cyano, haloalkyl, alkylthio, alkenyl, alkynyl, acylamino, tri or difluoromethoxy, carboxy, acyloxy, MeSO<sub>2</sub>- or R<sub>1</sub>, or the substituents at the 3 and 4 positions taken together form a fused ring which is a 5 or 6 membered carbocyclic or heterocyclic ring optionally substituted by halo, haloalkoxy,

Serial No. 10/030,189

Response to Office Action of July 1, 2003

haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or  $R_{1j}$ , and optionally substituted in the position alpha to the X-X group (i.e. 6 position for a six membered aromatic ring etc) by amino, hydroxy, halo, alkyl, carboxy, alkoxy, carbonyl, cyano, amido, aminoalkyl, alkoxy or alkylthio with the proviso that  $R_2$  cannot be aminoisoquinolyl;

each X independently is a C, N, O or S atom or a CO,  $CR_{1a}$ ,  $C(R_{1a})_2$  or  $NR_{1a}$  group, at least one X being C, CO,  $CR_{1a}$  or  $C(R_{1a})_2$ ;

each  $R_{1a}$  independently represents hydrogen, hydroxyl, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, carbonyl, alkylaminocarbonyl, alkoxy, carbonyl, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl;

$R_1$  is as defined for  $R_{1a}$ , provided that  $R_1$  is not unsubstituted aminoalkyl;

Y (the  $\alpha$ -atom) is a nitrogen atom or a  $CR_{1b}$  group;

Cy is a saturated or unsaturated, mono or poly cyclic, homo or heterocyclic group, preferably containing 5 to 10 ring atoms and optionally substituted by groups  $R_{3a}$  or phenyl optionally substituted by  $R_{3a}$ ;

each  $R_{3a}$  independently is  $R_{1c}$ , amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkyl imidazolyl, thiazolyl, alkyl thiazolyl, alkyl oxazolyl, oxazolyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy and haloalkyl; and


$R_{1b}$ ,  $R_{1c}$  and  $R_{1j}$  are as defined for  $R_{1a}$ ,

L is CO;

and  $-Lp(D)_n - L - Lp(D)_n$  is of the formula:

Serial No. 10/030,189

Response to Office Action of July 1, 2003



wherein:





q is 1 or 2;

Q is -O- or -NH-;



and R<sub>q</sub> is R<sub>C</sub> which is pyridyl or phenyl (which phenyl may bear a fluoro, chloro, methyl, CONH<sub>2</sub>, SO<sub>2</sub>NH<sub>2</sub>, methylaminosulphonyl, dimethylaminosulphonyl, methylsulphonylamino, methoxy or methylsulphonyl substituent); or a physiologically-tolerable salt thereof.

3 (canceled):

4 (currently amended): A compound according to claim 2 wherein -Lp(D)n is selected from the following formulae:



Serial No. 10/030,189  
Response to Office Action of July 1, 2003









wherein:

m represents 0 or 1; and

when R<sub>3</sub> is present as a substituent on an aromatic ring, it is selected from hydrogen, alkylsulphonyl, aminosulphonyl, alkylaminosulphonyl, alkylaminocarbonyl, amino, amido, alkoxycarbonyl, acetyl amino, chloro, fluoro, cyano, methoxy, ethoxy, nitro, hydroxy, alkylsulphonylamino, triazolyl and tetrazolyl.

5 (previously presented): A compound according to claim 2 wherein -Lp(D)<sub>n</sub> is selected from the following formulae:



Serial No. 10/030,189  
Response to Office Action of July 1, 2003

6 (previously presented): A compound according to claim 1 wherein Q is -NH-.

7 (previously presented): A compound according claim 1 wherein R<sub>c</sub> is pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimid-4-yl or phenyl.


8 (previously presented): A compound according to claim 1 wherein R<sub>c</sub> is phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-methylsulfonylphenyl, 2-methylthiophenyl, pyrid-2-yl, pyrid-3-yl or pyrid-4-yl.

9 (previously presented): A compound according to claim 1 wherein R<sub>2</sub> is phenyl, thien-2-yl, naphthyl, indol-2-yl, indol-6-yl, benzo[b]furan-5-yl, benzo[b]thiophen-2-yl or benzimidazol-2-yl (each of which is optionally substituted as defined in claim 1).

10 (previously presented): A compound according to claim 1 wherein optional substituents for R<sub>2</sub> are selected from: fluoro, chloro, bromo, iodo, nitro, thiol, difluoromethoxy, trifluoromethoxy, hydrazido, methylhydrazido, amino, cyano, trifluoromethyl, methylthio, vinyl, ethynyl, acetylamino, carboxy, acetoxy, hydroxy, methyl, ethyl, amido (CONH<sub>2</sub>), aminomethyl, methoxy and ethoxy.

11 (previously presented): A compound according to claim 1 wherein R<sub>2</sub> is selected from one of the formula (A') to (H'):

Serial No. 10/030,189  
Response to Office Action of July 1, 2003



wherein  $X_4$  is O or S,  $R_{13}$  is selected from hydrogen, chloro or methyl and  $R_{14}$  is selected from hydrogen, methyl, ethyl, fluoro, chloro, and methoxy and  $R_{15}$  is selected from hydrogen, methyl, fluoro, chloro and amino.

12 (original): A compound according to claim 11, wherein  $R_2$  is 4-methoxyphenyl, 5-chloroindol-2-yl, 3-chloroindol-6-yl, indol-6-yl or 3-methylindol-6-yl.



Serial No. 10/030,189  
Response to Office Action of July 1, 2003

13 (previously presented): A compound according to claim 1 wherein -X-X- is -CONH-.

14 (previously presented): A compound according to any one of claims 1 to 13, 15 to 16 and 19 to 22 wherein Y is CH.

15 (previously presented): A compound according to claim 1 wherein Cy is an optionally R<sub>3a</sub> substituted: phenyl, pyridyl, thienyl, thiazolyl, naphthyl, piperidinyl, furanyl, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, imidazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, pyrimidinyl, pyridazinyl, quinolyl, isoquinolyl, benzofuryl, benzothienyl or cycloalkyl group, or a phenyl group substituted by R<sub>3i</sub>X<sub>i</sub> in which X<sub>i</sub> is a bond, O, NH or CH<sub>2</sub> and R<sub>3i</sub> is phenyl or pyridyl optionally substituted by R<sub>3a</sub>.

16 (previously presented): A compound according to claim 2, wherein Cy is an optionally R<sub>3a</sub> substituted: phenyl, pyridyl, thienyl, thiazolyl, naphthyl, piperidinyl or cycloalkyl group.

17 (canceled):

18 (canceled):

19 (previously presented): A compound according to claim 1 wherein R<sub>3a</sub> is selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl, ethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl, carboxy, methoxymethyl, methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminomethyl, CONH<sub>2</sub>, CH<sub>2</sub>CONH<sub>2</sub>, acetyl amino, methoxycarbonylamino, ethoxycarbonylamino, t-butoxycarbonylamino, amino, fluoro, chloro, bromo, cyano, nitro, thiol, methylthio, methylsulphonyl, ethylsulphonyl,

Serial No. 10/030,189  
Response to Office Action of July 1, 2003


methylsulphenyl, methylsulphonylamido, ethylsulphonylamido, methylaminosulphonyl, ethylaminosulphonyl, aminosulphonyl, trifluoromethoxy, trifluoromethyl, bromo, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-1-ylcarbonyl and -OCH<sub>2</sub>O- (which is bonded to two adjacent ring atoms in Cy).

20 (previously presented): A compound according to claim 2 wherein R<sub>3a</sub> is selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl, ethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl, carboxy, methoxymethyl, methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminomethyl, CONH<sub>2</sub>, CH<sub>2</sub>CONH<sub>2</sub>, acetylamino, methoxycarbonylamino, ethoxycarbonylamino, t-butoxycarbonylamino, amino, fluoro, chloro, cyano, nitro, thiol, methylthio, methylsulphonyl, ethylsulphonyl, methylsulphenyl, methylsulphonylamido, ethylsulphonylamido, methylaminosulphonyl, ethylaminosulphonyl, aminosulphonyl, trifluoromethoxy and trifluoromethyl.

21 (previously presented): A compound according to claim 1 wherein Cy is selected from:

Serial No. 10/030,189

Response to Office Action of July 1, 2003



wherein:

X' is selected from O, S and NMe;

X'' is selected from O and S;

X''' is selected from O, S, NH and NMe;

Y' is selected from hydrogen, amino and methyl;

R<sub>o</sub> is selected from hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, methylthio, methylsulphinyl and methylsulphonyl;

R<sub>m</sub> is selected from hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, methylthio, methylsulphinyl, methylsulphonyl, carboxy, methoxycarbonyl and a group of the formula -C(X<sup>3</sup>)N(R<sup>11</sup>)R<sup>12</sup> (wherein X<sup>3</sup> is O or S, and R<sup>11</sup> and R<sup>12</sup> are independently selected from hydrogen, methyl or ethyl or

Serial No. 10/030,189

Response to Office Action of July 1, 2003

together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group);  $R_p$  is selected from hydrogen and fluoro; or  $R_o$  and  $R_m$  or  $R_m$  and  $R_p$  form an -OCH<sub>2</sub>O- group; or  $R_o$  and  $R_m$  together with the ring to which they are attached form a 5 or 6 membered aryl or heteroaryl ring (wherein the heteroaryl ring contains 1 or 2 heteroatoms selected from nitrogen, oxygen and sulfur); and one of  $R_{o1}$  and  $R_{o2}$  is hydrogen and the other is  $R_o$ .

22 (previously presented): A compound according to claim 1 wherein Cy is selected from phenyl, 2-chlorophenyl, 2-methoxyphenyl, 4-carbamoylphenyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, imidazol-2-yl, thiazol-2-yl, thiazol-4-yl, 2-amino-thiazol-4-yl, thiazol-5-yl, naph-1-thyl, isoquinolin-5-yl, isoquinolin-8-yl, quinolin-4-yl, quinolin-5-yl and quinolin-8-yl.

23 (original): A compound as claimed in Claim 1, which is selected from 1-(indol-6-carbonyl-D-phenylglyciny)-4-(4-pyridoxy)piperidine; 1-[indole-6-carbonyl-D,L-(2-chlorophenyl)glyciny]-4-(pyridin-4-yloxy)piperidine, and physiologically-tolerable salts thereof.

24 (previously presented): A compound as claimed in Claim 14, in which the alpha atom in Y is carbon and has the conformation that would result from construction from a D- $\alpha$ -aminoacid NH<sub>2</sub>-CR<sub>1b</sub>(Cy)-COOH where the NH<sub>2</sub> represents part of X-X.

25 (previously presented): A pharmaceutical composition, which comprises a compound as claimed in Claim 1 together with at least one pharmaceutically acceptable carrier or excipient.

Serial No. 10/030,189  
Response to Office Action of July 1, 2003

26 (canceled):

27 (canceled):

28 (canceled):

29 (original): A method of treatment of the human or non-human animal body to combat a thrombotic disorder, said method comprising administering to said body an effective amount of a compound according to Claim 1.









30 (canceled):

31 (previously presented): A compound as claimed in Claim 1, in which

R<sub>2</sub> is selected from one of the formula (A') to (H'):

Serial No. 10/030,189

Response to Office Action of July 1, 2003




wherein  $X_4$  is O or S,  $R_{13}$  is selected from hydrogen, chloro or methyl and  $R_{14}$  is selected from hydrogen, methyl, ethyl, fluoro, chloro, and methoxy and  $R_{15}$  is selected from hydrogen, methyl, fluoro, chloro and amino;

-X-X- is -CONH-;

Y is CH and has the conformation that would result from construction from a D- $\alpha$ -aminoacid  $NH_2-CR_{1b}(Cy)-COOH$  where the  $NH_2$  represents part of X-X; and

Cy is selected from:

Serial No. 10/030,189  
Response to Office Action of July 1, 2003



wherein:

X' is selected from O, S and NMe;

X'' is selected from O and S;

X''' is selected from O, S, NH and NMe;

Y' is selected from hydrogen, amino and methyl;

R<sub>o</sub> is selected from hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, methylthio, methylsulphinyl and methylsulphonyl;

R<sub>m</sub> is selected from hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, methylthio, methylsulphinyl, methylsulphonyl, carboxy, methoxycarbonyl and a group of the formula -C(X<sup>3</sup>)N(R<sup>11</sup>)R<sup>12</sup> (wherein X<sup>3</sup> is O or S, and R<sup>11</sup> and R<sup>12</sup> are independently selected from hydrogen, methyl or ethyl or

Serial No. 10/030,189

Response to Office Action of July 1, 2003

together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group);  $R_p$  is selected from hydrogen and fluoro; or  $R_o$  and  $R_m$  or  $R_m$  and  $R_p$  form an  $-OCH_2O-$  group; or  $R_o$  and  $R_m$  together with the ring to which they are attached form a 5 or 6 membered aryl or heteroaryl ring (wherein the heteroaryl ring contains 1 or 2 heteroatoms selected from nitrogen, oxygen and sulfur); and one of  $R_{o1}$  and  $R_{o2}$  is hydrogen and the other is  $R_o$ .

32 (previously presented): A compound according to Claim 31, in which

$R_2$  is 4-methoxyphenyl, 5-chloroindol-2-yl, 3-chloroindol-6-yl, indol-6-yl or 3-methylindol-6-yl;

Cy is selected from phenyl, 2-chlorophenyl, 2-methoxyphenyl, 4-carbamoylphenyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, imidazol-2-yl, thiazol-2-yl, thiazol-4-yl, 2-amino-thiazol-4-yl, thiazol-5-yl, naph-1-thyl, isoquinolin-5-yl, isoquinolin-8-yl, quinolin-4-yl, quinolin-5-yl and quinolin-8-yl; and

$R_c$  is phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-methylsulfonylphenyl, 2-methylthiophenyl, pyrid-2-yl, pyrid-3-yl or pyrid-4-yl.

33 (previously presented): A compound according to Claim 2, in which

$R_2$  represents:

(1) phenyl optionally being substituted in the 3 and/or 4 position by fluoro, chloro, bromo, iodo, nitro, difluoromethoxy, trifluoromethoxy, amino, cyano, trifluoromethyl, methylthio, vinyl, carboxy, acetoxy,  $MeSO_2-$ , hydroxy, methoxy, ethoxy, methyl, methoxycarbonyl,



Serial No. 10/030,189

Response to Office Action of July 1, 2003

methylamino, ethylamino or amido, and optionally substituted at the 6 position by amino, hydroxy, fluoro, methoxycarbonyl, cyano or aminomethyl;

(ii) naphth-2-yl optionally substituted at the 6, position by hydroxy and optionally substituted at the 3 position by amino or hydroxy;

(iii) isoquinolin-7-yl, indol-5-yl, indol-6-yl, indazol-5-yl, indazol-6-yl, benzothiazol-6-yl or benzisoxazol-5-yl optionally substituted at the 3 position by chloro, bromo, amino, methyl or methoxy;

(iv) benzimidazol-5-yl or benzothiazol-6-yl optionally substituted at the 2 position by amino;

(v) thien-2-yl or thien-3-yl optionally substituted at the 4 or 5 position by methylthio, methyl or acetyl;

(vi) 3,4-methylenedioxyphenyl, 2,3-dihydroindol-6-yl, 3,3-dichloro-2-oxo-indol-6-yl or 1-methyl-3-aminoindazol-5-yl;

(vii) benzothiazol-2-yl, imidazo[1,2-a]pyrimidin-2-yl or tetrahydroimidazo[1,2-a]pyrimidin-2-yl;

(viii) pyrazol-2-yl substituted at the 5 position by methyl;

(ix) pyrid-2-yl optionally substituted at the 6 position by chloro;

(x) pyrid-3-yl optionally substituted at the 4 position by chloro;

(xi) benzofur-2-yl optionally substituted at the 3 position by chloro, methyl or methoxy, at the 5 or 6 position by methyl and at the 6 position by methoxy;

(xii) indol-2-yl optionally substituted on the indole nitrogen atom by methyl and optionally substituted at the 5 or 6 position by fluoro, chloro, bromo, methyl or methoxy;

(xiii) indol-6-yl substituted at the 5 position by chloro, fluoro or hydroxy and optionally substituted at the 3 position by chloro or methyl; or

Serial No. 10/030,189

Response to Office Action of July 1, 2003





(xiv) benzo[b]thiophen-2-yl optionally substituted at the 3 position by fluoro, chloro or methyl, and optionally substituted at the 5 or 6 position by fluoro, chloro, methyl, hydroxy, or methoxy;

-X-X- is -CONH-;



Y is CH and has the conformation that would result from construction from a D- $\alpha$ -aminoacid  $\text{NH}_2\text{-CR}_{1b}(\text{Cy})\text{-COOH}$  where the  $\text{NH}_2$  represents part of X-X; and

Cy is selected from phenyl, 4-aminophenyl, 4-amidophenyl, 4-(N-methyl)amidophenyl, 4-(N,N-dimethyl)amidophenyl, 2-chlorophenyl, 2-methylphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 4-methoxyphenyl, 4-carboxyphenyl, 3-ethylsulphonylaminophenyl, thien-2-yl, thien-3-yl, thiazol-4-yl, thiazol-5-yl, 2-methylthiazol-4-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, piperidin-4-yl, 1-methylpiperidin-4-yl, cyclohexyl and naphth-1-yl.

34 (currently amended): A compound according to Claim 33, in which -Lp(D)n is selected from the following formulae:



Serial No. 10/030,189  
Response to Office Action of July 1, 2003



wherein:

m represents 0 or 1; and

when R<sub>3</sub> is present as a substituent on an aromatic ring, it is selected from hydrogen, alkylsulphonyl, aminosulphonyl, alkylaminosulphonyl, alkylaminocarbonyl, amino, amido, alkoxycarbonyl, acetyl amino, chloro, fluoro, cyano, methoxy, ethoxy, nitro, hydroxy, alkylsulphonylamino, triazolyl and tetrazolyl.

35 (previously presented): A compound according to Claim 33, in which

-Lp(D)n is selected from the following formulae:

